2 results
Approved WMOCompleted
To study the effect on intraocular pressure in patients using the Travalert dosing aid with or without the additional use of the Eyot and with of without additional patient education.
Approved WMORecruiting
Primary ObjectiveTo assess the effect of ALX148 plus pembrolizumab on 12-month overall survival (OS) rate and objective response rate (ORR) in patients withmetastatic or with unresectable, recurrent HNSCC that is PD-L1 positive (CPS >=1) and…